ArticleFunctional & integrative genomics2025
Increased CDKN2A expression correlates with resistance to platinum-based therapy and decreased infiltration of B lymphocytes in colon adenocarcinoma.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The Senescence-SASP Landscape in Colon Adenocarcinoma: Prognostic and Therapeutic Implications.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCuproptosis-related gene CDKN2A is involved in the development and progression of various solid tumors. However, the potential involvement of CDKN2A in colon adenocarcinoma (COAD) remains unexplored.
methodsThe expression profiles of cuproptosis-related genes in COAD and their relationships with survival prognosis were analyzed using TCGA and GEO bulk RNA-sequencing datasets. Subsequently, enrichment analysis, genomic mutation analysis, drug sensitivity analysis, and immune infiltration analysis were conducted to assess the significance of CDKN2A in COAD. Using a single-cell RNA-sequencing dataset, we investigated the intercellular communication networks among B lymphocytes according to CDKN2A expression. Furthermore, the potential roles of CDKN2A in COAD were validated through a series of in vitro experiments.
resultsCDKN2A was highly expressed in COAD, contributing to platinum resistance through its association with extracellular matrix organization and DNA adduct chemical carcinogenesis. It correlated with the Wnt and Hippo signaling pathway, poor prognosis, and reduced B lymphocyte infiltration, but was not a major oncogenic driver in COAD. Elevated CDKN2A altered the communication patterns between non-switched memory B cells and switched memory B cells. Notably, small interfering RNA-mediated knockdown of CDKN2A in COAD inhibited glycolysis, promoted cuproptosis, and suppressed tumor proliferation, invasion and migration.
conclusionOur study demonstrated that the cuproptosis-related gene CDKN2A is a promising prognostic biomarker in COAD and may potentially guide the personalized chemotherapy regimens for COAD patients.
Indexed as
Identifiers
40608130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.